Bøger af Tim Serno

Advances in molecular genetics and recombinant protein (rDNA) technology lead to anincreasing availability of protein-based biomolecules1. In contrast to conventional lowmolecular weight synthetic chemical drugs protein drugs provide a relatively high specifityand activity at low concentrations2. Therefore, today protein drugs represent a fast-growingclass of therapeutic molecules1,3. Protein-based drugs offer a multitude of new therapeuticoptions, mainly for the treatment of severe and chronic diseases such as autoimmune orcancer diseases2. However, with the increasing number of ¿new biologic entities¿ passingthrough development and manufacturing and finally reaching patients, also unprecedentedchallenges for the design of stable, safe and convenient formulations are encountered4.The first obvious formulation challenge to be faced concerns the delivery of protein drugs.Oral delivery ¿ which is generally the preferred and most widely applied route of drugadministration ¿ is not feasible with protein drugs.